| (Values in U.S. Thousands) | Mar, 2023 | Sep, 2022 | Jun, 2022 | Mar, 2022 | Sep, 2021 |
| Sales | 0 | 0 | 0 | 0 | 4 |
| Sales Growth | unch | unch | unch | -100.00% | +0.79% |
| Net Income | -4,959 | -7,266 | -5,957 | -2,745 | -2,467 |
| Net Income Growth | +31.74% | -21.97% | -117.01% | -11.29% | -7.36% |
Promis Neurosciences Inc (PMN.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
Fiscal Year End Date: 12/31